BIO-TECHNE CORP.

ISIN: US09073M1045 WKN: 09073M104 Asset Class: Stock



Company Profile

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Financial figures, Fiscal year: from 01.07. to 30.06.

	202	24	20	23	202	22
Financial figures	Assets Liabilities and equity		Assets Liabilities and equity		Assets Liabilities and equity	
Current assets	617,419,000		621,482,000		605,556,000	
Common stock capital		-		1,576,000		392,000
Fixed assets	2,086,448,000		2,112,233,000		1,765,472,000	
Equity capital of a company		2,068,850,000		1,966,516,000		1,701,011,000
Cash and cash equivalents	151,791,000		180,571,000		172,567,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		159,379,000		128,509,000		176,018,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		475,638,000		638,690,000		493,999,000
Different income		-		-		-
Other liabilities		13,157,000		10,919,000		17,239,000
Total assets	2,703,867,000	2,703,867,000	2,733,715,000	2,733,715,000	2,371,028,000	2,371,028,000

Balance notes

	2024	2023	2022
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	-	3,050	3,000
Equity ratio	76.51%	71.94%	71.71%
Debt-equity ratio	30.69%	39.01%	39.45%

Others

	2024	2023	2022
Tax Expense Rate	9.47%	15.71%	12.70%

BIO-TECHNE CORP.

ISIN:	US09073M1045	WKN:	09073M104	Asset Class:	Stock

Income statement

	2024	2023	2022
Turnover	1,159,060,000	1,136,702,000	1,105,599,000
Net income	168,105,000	285,193,000	271,930,000
EBIT	168,884,146	318,249,512	289,451,104
Operating income before taxes	185,689,000	338,659,000	301,386,000
Cash Flow	298,981,000	254,393,000	325,272,000
Net interest income	-	-11,258,000	-16,867,000
Research and development expenses	96,664,000	92,493,000	87,140,000
Income taxes	17,584,000	53,217,000	38,287,000
Result from investments in subsidaries, associates and other	-	0	0
Revenues per employee	-	338,961	335,181

Board of Directors

Members of Management Board

Robert Baumgartner	Chairman of Board of Directors	
Alpna Seth	Member of Board of Directors	
Joseph Keegan	Member of Board of Directors	
Judith Klimovsky	Member of Board of Directors	
Randolph Steer	Member of Board of Directors	
Roeland Nusse	Member of Board of Directors	
Rupert Vessey	Member of Board of Directors	
John Higgins	Member of Board of Directors	
Julie Bushman	Member of Board of Directors	
Charles Kummeth	Chairman of Managing Board	
Brenda S. Everson	Member of Executive Committee	
Jim Hippel	Member of Executive Committee	
Kevin Smyth	Member of Executive Committee	